Hayato Iwase1, Hidetaka Hara1, Mohamed Ezzelarab1, Tao Li1,2, Zhongqiang Zhang1,3, Bingsi Gao1,2, Hong Liu1,4, Cassandra Long1, Yi Wang2, Amy Cassano5, Edwin Klein5, Carol Phelps6, David Ayares6, Abhinav Humar1, Martin Wijkstrom1, David K C Cooper1. 1. Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA. 2. Center for Kidney Transplantation, Second Affiliated Hospital of the University of South China, Hengyang, Hunan, China. 3. Department of General Surgery, Second Xiangya Hospital of the Central South University, Changsha, Hunan, China. 4. Department of General Surgery, First Hospital of Shanxi Medical University, Taiyuan, China. 5. Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, PA, USA. 6. Revivicor, Blacksburg, VA, USA.
Abstract
BACKGROUND: Genetically engineered pigs could provide a source of kidneys for clinical transplantation. The two longest kidney graft survivals reported to date have been 136 and 310 days, but graft survival >30 days has been unusual until recently. METHODS: Donor pigs (n=4) were on an α1,3-galactosyltransferase gene-knockout (GTKO)/human complement regulatory protein (CD46) background (GTKO/CD46). In addition, the pigs were transgenic for at least one human coagulation regulatory protein. Two baboons received a kidney from a six-gene pig (GroupA) and two from a three-gene pig (GroupB). Immunosuppressive therapy was identical in all four cases and consisted of anti-thymoglobulin (ATG)+anti-CD20mAb (induction) and anti-CD40mAb+rapamycin+corticosteroids (maintenance). Anti-TNF-α and anti-IL-6R mAbs were administered to reduce the inflammatory response. Baboons were followed by clinical/laboratory monitoring of immune/coagulation/inflammatory/physiological parameters. At biopsy or euthanasia, the grafts were examined by microscopy. RESULTS: The two GroupA baboons remained healthy with normal renal function >7 and >8 months, respectively, but then developed infectious complications. However, no features of a consumptive coagulopathy, eg, thrombocytopenia and reduction of fibrinogen, or of a protein-losing nephropathy were observed. There was no evidence of an elicited anti-pig antibody response, and histology of biopsies taken at approximately 4, 6, and 7 months and at necropsy showed no significant abnormalities. In contrast, both GroupB baboons developed features of a consumptive coagulopathy and required euthanasia on day 12. CONCLUSIONS: The combination of (i) a graft from a specific six-gene genetically modified pig, (ii) an effective immunosuppressive regimen, and (iii) anti-inflammatory therapy prevented immune injury, a protein-losing nephropathy, and coagulation dysfunction for >7 months. Although the number of experiments is very limited, our impression is that expression of human endothelial protein C receptor (±CD55) in the graft is important if coagulation dysregulation is to be avoided.
BACKGROUND: Genetically engineered pigs could provide a source of kidneys for clinical transplantation. The two longest kidney graft survivals reported to date have been 136 and 310 days, but graft survival >30 days has been unusual until recently. METHODS:Donorpigs (n=4) were on an α1,3-galactosyltransferase gene-knockout (GTKO)/human complement regulatory protein (CD46) background (GTKO/CD46). In addition, the pigs were transgenic for at least one human coagulation regulatory protein. Two baboons received a kidney from a six-gene pig (GroupA) and two from a three-gene pig (GroupB). Immunosuppressive therapy was identical in all four cases and consisted of anti-thymoglobulin (ATG)+anti-CD20mAb (induction) and anti-CD40mAb+rapamycin+corticosteroids (maintenance). Anti-TNF-α and anti-IL-6R mAbs were administered to reduce the inflammatory response. Baboons were followed by clinical/laboratory monitoring of immune/coagulation/inflammatory/physiological parameters. At biopsy or euthanasia, the grafts were examined by microscopy. RESULTS: The two GroupA baboons remained healthy with normal renal function >7 and >8 months, respectively, but then developed infectious complications. However, no features of a consumptive coagulopathy, eg, thrombocytopenia and reduction of fibrinogen, or of a protein-losing nephropathy were observed. There was no evidence of an elicited anti-pig antibody response, and histology of biopsies taken at approximately 4, 6, and 7 months and at necropsy showed no significant abnormalities. In contrast, both GroupB baboons developed features of a consumptive coagulopathy and required euthanasia on day 12. CONCLUSIONS: The combination of (i) a graft from a specific six-gene genetically modified pig, (ii) an effective immunosuppressive regimen, and (iii) anti-inflammatory therapy prevented immune injury, a protein-losing nephropathy, and coagulation dysfunction for >7 months. Although the number of experiments is very limited, our impression is that expression of humanendothelial protein C receptor (±CD55) in the graft is important if coagulation dysregulation is to be avoided.
Authors: P Thompson; I R Badell; M Lowe; J Cano; M Song; F Leopardi; J Avila; R Ruhil; E Strobert; G Korbutt; G Rayat; R Rajotte; N Iwakoshi; C P Larsen; A D Kirk Journal: Am J Transplant Date: 2011-08-29 Impact factor: 8.086
Authors: Hayato Iwase; Burcin Ekser; Vikas Satyananda; Mohamed Ezzelarab; David K C Cooper Journal: Xenotransplantation Date: 2014-07-08 Impact factor: 3.907
Authors: Donald G Harris; Kevin J Quinn; Beth M French; Evan Schwartz; Elizabeth Kang; Siamak Dahi; Carol J Phelps; David L Ayares; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson Journal: Xenotransplantation Date: 2014-12-02 Impact factor: 3.907
Authors: Mohamed B Ezzelarab; Burcin Ekser; Gabriel Echeverri; Hidetaka Hara; Corin Ezzelarab; Cassandra Long; Pietro Bajona; Bertha Garcia; Noriko Murase; David Ayares; David K C Cooper Journal: Xenotransplantation Date: 2012 Jul-Aug Impact factor: 3.907
Authors: David K C Cooper; Vikas Satyananda; Burcin Ekser; Dirk J van der Windt; Hidetaka Hara; Mohamed B Ezzelarab; Henk-Jan Schuurman Journal: Xenotransplantation Date: 2014-09-01 Impact factor: 3.907
Authors: Hayato Iwase; Burcin Ekser; Hidetaka Hara; Mohamed B Ezzelarab; Cassandra Long; Angus W Thomson; David Ayares; David K C Cooper Journal: Xenotransplantation Date: 2016-07-04 Impact factor: 3.907
Authors: Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Marvin L Thomas Iii; Tannia Clark; Billeta G Lewis; Robert F Hoyt; Michael Eckhaus; Richard N Pierson Iii; Aaron J Belli; Eckhard Wolf; Nikolai Klymiuk; Carol Phelps; Keith A Reimann; David Ayares; Keith A Horvath Journal: Nat Commun Date: 2016-04-05 Impact factor: 14.919
Authors: Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase Journal: Transpl Immunol Date: 2018-08-06 Impact factor: 1.708
Authors: Hironosuke Watanabe; Yuichi Ariyoshi; Thomas Pomposelli; Kazuhiro Takeuchi; Dilrukshi K Ekanayake-Alper; Lennan K Boyd; Scott J Arn; Hisashi Sahara; Akira Shimizu; David Ayares; Marc I Lorber; Megan Sykes; David H Sachs; Kazuhiko Yamada Journal: Xenotransplantation Date: 2019-09-23 Impact factor: 3.907